Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • HeraMED’s (ASX:HMD) distributor in India has secured a service partnership with Cloudnine Hospital Group
  • HeraMED’s HeraBEAT foetal heart rate monitors will be made available for Cloudnine customers to rent
  • The heart rate monitor allows expectant mothers to monitor their foetus’ heartbeat anytime, anywhere
  • HeraMED has ended the day down 14 per cent with shares trading for 18.5 cents apiece

Medical Technology company HeraMED’s distributor based in India has secured a service partnership with Cloudnine Hospital Group.

Cloudnine is a leading chain of maternity, childcare and fertility hospitals in India.

Founded in 2007, and headquartered in India’s high-tech industry in Bangalore, Cloudnine’s vision is to effectively bridge the gap between Indian and international standards of women and child healthcare.

This partnership will see the distributor initiate a pilot which allows expectant mothers in the Cloudnine network to rent the HeraBEAT smart foetal heart rate monitor for home use.

HeraBEAT is HeraMED’s medically accurate, scientifically optimised, smartphone-based heartbeat monitor for home use.

By using sophisticated technology and professional accuracy it allows expectant mothers to monitor their foetus’ heartbeat anytime, anywhere.

The data can then be stored and shared to medical professionals which enable parents to rest while their foetus is receiving medical attention.

The cooperation was signed with HeraMED’s Indian distribution partner, Consultus India, and the devices will be sold under their H-Cube short form, which is short for Her Healthcare at Home brand.

As a first step, H-Cube has focused itself on pregnancy care and monitoring solutions.

Along with HeraBEAT, H-Cube has been introduced to the Indian market at a natural childbirth preparation device. H-Cube is committed to introducing unique products and solutions for pregnancy home care for Indian women.

“Our market entry into India is showing positive progress in a short period of time. The Company’s technology has received another strong acknowledgement from a leading healthcare institution,” CEO and Cofounder David Groberman said.

“The HeraBEAT provides a gold standard alternative to significantly more expensive competitor products and we are glad to have the opportunity to provide the device and peace of mind to expecting mothers in India,” he added.

Despite this new, HeraMED has ended the day down 14 per cent with shares trading for 18.5 cents apiece in an $18.81 million market cap.

HMD by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

" Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) has been granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients.